RNS & Investor News

Grant of Options and PDMR Dealing

25 September 2018

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announces the grant of options to its newly appointed non executive director, Sean Christie. The options were granted on Friday 21 September 2018 at an exercise price of 95p. Full details of the options agreement are set out in the table below.

Number of Shares under option 100,000
Exercise Price 95p
Expiration date 21 September 2028
Interests following grant (shares/options) 100,000

The options have performance criteria attached to them which requires a doubling in the share price. The option holder can only purchase and/or sell shares once these conditions have been met. This ensures a continued focus on shareholder value creation.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 and the person who arranged for release of this announcement on behalf of the Company was Stephen O'Hara, Chief Executive.

Stephen O'Hara, CEO of OptiBiotix, commented: "The ability to attract industry leading board members who deliver to performance targets and build shareholder value is important to OptiBiotix's continued success. The granting of share options helps OptiBiotix compete with the remuneration packages offered by larger corporates and incentivises the board to focus both effort and activity on building shareholder value. These options are offered to staff do not become exercisable (i.e. sellable) until they achieve performance targets which if achieved will create substantive shareholder value."


For further information, please contact:

OptiBiotix Health Plc
Stephen O'Hara, Chief Executive
Contact via Walbrook below
Cairn Financial Advisers LLP
Liam Murray / Jo Turner / Ludovico Lazzaretti
Tel: 020 7213 0880
finnCap (Broker)
Geoff Nash/ Scott Mathieson / Kate Bannatyne (Corporate Finance)
Camille Gochez (Corporate Broking)
Tel: 020 7220 0500
Walbrook PR Ltd
Anna Dunphy
Tel: 020 7933 8780 or [email protected]
Mob: 07876 741 001


About OptiBiotix - www.optibiotix.com

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D program working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.


Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1 Details of the person discharging managerial responsibilities/person closely associated
a. Name Sean Christie
2 Reason for notification
a. Position/Status Non-executive Director of the Company
b. Initial notification / Amendment Initial Notification
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a. Name OptiBiotix Health Plc
b. LEI 213800UKYQFT941QHS14
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a. Description of the financial instrument, type of instrument

Identification Code

Options over 100,000 ordinary shares of 2p each

b. Nature of the transaction Award of option to purchase ordinary shares of the Company. Following the transaction, Mr Sean Christie has an interest in options over 100,000 ordinary shares.
c. Price(s) and volume(s)
Price(s) per share Volume(s)
95p 100,000
d. Aggregated information

- Aggregated Volume
- Price

e. Date of the transaction 21 September 2018
f. Place of the transaction London Stock Exchange, AIM